$CRL (Charles River Laboratories International, Inc.)

$CRL {{ '2016-10-11T12:50:25+0000' | timeago}} • Announcement

$CRL extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group. $CRL provides Genentech early discovery services to help identify promising candidates for preclinical development.

$CRL {{ '2018-01-11T13:12:01+0000' | timeago}} • Announcement

Drug research solutions provider $CRL has acquired KWS BioTest, a contract research organization, for about $20MM. The deal also includes a potential additional payment of up to $4MM based on future performance. The acquisition is not expected to be material to Charles River’s GAAP or non-GAAP results from operations this year.

$CRL {{ '2017-10-04T15:17:39+0000' | timeago}} • Announcement

$CRL and Trax, a subsidiary of MarketAxess Holdings, Inc., have agreed to integrate Trax’s MiFID II Trade and Transaction reporting solutions into the Charles River Investment Management Solution. This will help clients of both firms to use the Trax Approved Publication Arrangement to publish trade reports and transaction report trades.

$CRL {{ '2017-08-07T12:06:03+0000' | timeago}} • Announcement

$CRL has acquired Brains On-Line, a contract research organization providing critical data, for approx $21MM.  In addition to the initial purchase price, the transaction includes potential additional payments of up to about $8MM based on future performance.

$CRL {{ '2017-07-05T12:50:22+0000' | timeago}} • Announcement

$CRL appointed $ALXN EVP Dr Martin Mackay to its BoD.  As a member of the board, he will serve on the Corporate Governance and Nominating Committee and the Science and Technology Committee.

$CRL {{ '2017-05-10T12:09:25+0000' | timeago}} • Announcement

During 1Q17, $CRL reinitiated stock repurchase activity, repurchasing 363,000 shares for a total of $32.1MM. As of April 1, 2017, the company had $37.6MM remaining on its authorized stock repurchase program.

$CRL {{ '2017-05-10T12:07:08+0000' | timeago}} • Announcement

For FY17, $CRL reaffirmed its revenue guidance of growth in the range of 7.5-9%. It now expects GAAP EPS in the range of $4.18-4.33 and non-GAAP EPS between $5 and $5.15. $CRL expects organic revenue growth of 7-8.5%  during this period.

$CRL {{ '2017-05-10T12:02:07+0000' | timeago}} • Announcement

On a non-GAAP basis, $CRL reported net income from continuing operations of $62.6MM, or $1.29 per share in 1Q17, an increase of 34.4% from what it reported in the same period in 2016.

$CRL {{ '2017-05-10T11:58:21+0000' | timeago}} • Announcement

Laboratory services firm $CRL posted 25.6% growth in revenue to $445.8MM in 1Q17, driven by the Discovery and Safety Assessment and Manufacturing Support segments. Net income was $46.8MM, or $0.97 per share, compared to $37.1MM, or $0.78 per share in 1Q16. The higher earnings were driven by acquisition of new businesses, notably WIL Research.

$CRL {{ '2017-04-05T12:45:15+0000' | timeago}} • Announcement

Nimbus Therapeutics and $CRL launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.

$CRL {{ '2017-02-14T11:52:15+0000' | timeago}} • Announcement

$CRL expects 2017 revenue growth of 7.5-9% and organic revenue growth of 7-8.5%. The company predicts 2017 GAAP EPS of $4.33-4.43 and non-GAAP EPS of $5.00-5.10. EPS in 2017 are expected to benefit from both higher revenue and operating margin expansion.

$CRL {{ '2017-02-14T11:50:30+0000' | timeago}} • Announcement

$CRL reported a rise in 4Q16 earnings driven by Discovery and Safety Assessment and Manufacturing Support segments. Net income rose to $44.68MM or $0.93 per share from $31.88MM or $0.67 per share last year. Revenue grew to $466.79MM from $353.85MM. Non-GAAP EPS increased to $1.21 from $1.00.

$CRL {{ '2017-01-30T13:36:49+0000' | timeago}} • Announcement

$CRL announced a progress update related to its support of Moderna Therapeutics' nonclinical discovery and development efforts. Moderna’s current development pipeline includes 12 mRNA development candidates.

$CRL {{ '2016-10-11T12:50:25+0000' | timeago}} • Announcement

$CRL extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group. $CRL provides Genentech early discovery services to help identify promising candidates for preclinical development.

$CRL {{ '2016-09-28T21:25:36+0000' | timeago}} • Announcement

$CRL acquired bioanalytical researh service provider Agilux Laboratories. Agilux was acquired from a holding company controlled by the company’s founders and Ampersand Capital Partners, its only institutional investor.

$CRL {{ '2016-09-22T13:00:35+0000' | timeago}} • Announcement

$CRL entered into a strategic partnership agreement with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) intended to accelerate translation of discoveries into novel therapies for patients. $CRL will provide Tri-I TDI with discovery and safety assessment services to support range of projects that are at frontier of science.

$CRL {{ '2016-06-28T07:57:58+0000' | timeago}} • Announcement

$CRL, a service provider to the pharma industry, said it has acquired Massachusetts-based contract research organization, Blue Stream Labs. The combined company will have the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization. Terms of the acquisition were not disclosed.

$CRL {{ '2016-04-13T21:18:35+0000' | timeago}} • Announcement

Pharmaceutical products company $CRL said it has entered into a strategic partnership with BioMotiv to provide drug discovery and preclinical development services to BioMotiv's portfolio of technologies and companies. $CRL has committed to invest up to $10MM in BioMotiv.

$CRL {{ '2016-04-04T13:11:01+0000' | timeago}} • Announcement

Provider of products & services to pharma companies $CRL said that it has acquired WIL Research, a CDMO services provider to biopharmaceutical and agricultural companies, for approx. $585MM in cash, subject to certain customary adjustments.

$CRL {{ '2016-01-07T14:01:14+0000' | timeago}} • Announcement

$CRL's agreement to acquire WIL Research is also expected to add $240-250MM to $CRL's 2017 consolidated revenue and expected to be accretive to non-GAAP EPS by at least $0.20 in 2016 and $0.45-0.50 in 2017. The company expects to generate operational synergies from the acquisition, with benefits totaling $17-20MM within two years of closing.

$CRL {{ '2016-01-07T13:59:58+0000' | timeago}} • Announcement

Pre-clinical and clinical laboratory services provider $CRL agreed to acquire WIL Research for approx. $585MM in cash, subject to customary closing adjustments. The transaction is scheduled to close early in 2Q16. Based on the anticipated timing of the close, the acquisition is expected to add $150-170MM to $CRL's 2016 consolidated revenue.

Recent Transcripts

XON (Intrexon Corporation)
Thursday, November 9 2017 - 10:30pm
CRL (Charles River Laboratories International, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
SNMX (Senomyx Inc.)
Thursday, November 2 2017 - 9:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
EXAS (Exact Sciences Corporation)
Monday, October 30 2017 - 9:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
ICLR (ICON Public Limited Company)
Thursday, October 26 2017 - 2:00pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, October 26 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
PRAH (PRA Health Sciences, Inc.)
Thursday, October 26 2017 - 12:00pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm

AlphaGraphics you may like